Session » (1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM

Abstract Number: 1122

A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems

10:30AM-12:30PM

Abstract Number: 1105

Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors

10:30AM-12:30PM

Abstract Number: 1100

Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study

10:30AM-12:30PM

Abstract Number: 1107

Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium

10:30AM-12:30PM

Abstract Number: 1108

Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy

10:30AM-12:30PM

Abstract Number: 1112

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications

10:30AM-12:30PM

Abstract Number: 1094

Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects

10:30AM-12:30PM

Abstract Number: 1109

Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study

10:30AM-12:30PM

Abstract Number: 1111

Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study

10:30AM-12:30PM

Abstract Number: 1102

Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.

10:30AM-12:30PM

Abstract Number: 1089

Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry

10:30AM-12:30PM

Abstract Number: 1101

Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis

10:30AM-12:30PM

Abstract Number: 1115

Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes

10:30AM-12:30PM

Abstract Number: 1106

Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan

10:30AM-12:30PM

Abstract Number: 1113

Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort

10:30AM-12:30PM

Abstract Number: 1104

Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer

10:30AM-12:30PM

Abstract Number: 1096

Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.

10:30AM-12:30PM

Abstract Number: 1118

Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand

10:30AM-12:30PM

Abstract Number: 1117

Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review

10:30AM-12:30PM

Abstract Number: 1121

Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors

10:30AM-12:30PM

Abstract Number: 1119

Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors

10:30AM-12:30PM

Abstract Number: 1114

Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine

10:30AM-12:30PM

Abstract Number: 1097

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms

10:30AM-12:30PM

Abstract Number: 1092

Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

10:30AM-12:30PM

Abstract Number: 1090

Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study

10:30AM-12:30PM

Abstract Number: 1093

Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

10:30AM-12:30PM

Abstract Number: 1099

Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events

10:30AM-12:30PM

Abstract Number: 1091

Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study

10:30AM-12:30PM

Abstract Number: 1116

Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis

10:30AM-12:30PM

Abstract Number: 1120

Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F

10:30AM-12:30PM

Abstract Number: 1098

Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring

10:30AM-12:30PM

Abstract Number: 1095

Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series

10:30AM-12:30PM

Abstract Number: 1110

Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy

10:30AM-12:30PM

Abstract Number: 1088

Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry

10:30AM-12:30PM

Abstract Number: 1103

Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis